Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Novartis AG is a drug manufacturers-general business based in the US. Novartis shares (NVS) are listed on the NYSE and all prices are listed in US Dollars. Novartis employs 108,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $85.13 |
|---|---|
| 52-week range | $79.34 - $95.17 |
| 50-day moving average | $84.64 |
| 200-day moving average | $87.47 |
| Wall St. target price | $101.40 |
| PE ratio | 20.104 |
| Dividend yield | $3.4 (3.68%) |
| Earnings per share (TTM) | $4.33 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $85.13 from 2022-01-24
| 1 week (2022-01-14) | -5.99% |
|---|---|
| 1 month (2021-12-23) | -1.77% |
| 3 months (2021-10-21) | N/A |
| 6 months (2021-07-23) | -7.03% |
| 1 year (2021-01-25) | -13.55% |
|---|---|
| 2 years (2020-01-24) | -9.31% |
| 3 years (2019-01-25) | 0.38% |
| 5 years (2017-01-25) | 19.56% |
Valuing Novartis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Novartis shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novartis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1087. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.2 billion.
The EBITDA is a measure of a Novartis's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $52.4 billion |
|---|---|
| Operating margin TTM | 27.94% |
| Gross profit TTM | $35.5 billion |
| Return on assets TTM | 7.29% |
| Return on equity TTM | 17.6% |
| Profit margin | 18.72% |
| Book value | $25.38 |
| Market capitalisation | $194.8 billion |
TTM: trailing 12 months
Dividend payout ratio: 54.22% of net profits
Recently Novartis has paid out, on average, around 54.22% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.68% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis shareholders could enjoy a 3.68% return on their shares, in the form of dividend payments. In Novartis's case, that would currently equate to about $3.4 per share.
Novartis's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novartis's most recent dividend payout was on 14 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 3 March 2021 (the "ex-dividend date").
Novartis's shares were split on a 1116:1000 basis on 8 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis shares which in turn could have impacted Novartis's share price.
Over the last 12 months, Novartis's shares have ranged in value from as little as $79.34 up to $95.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis's is 0.556. This would suggest that Novartis's shares are less volatile than average (for this exchange).
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.